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OBJECTIVES: We evaluated mRNA expression levels of genes that encode TGF-b1; the TGF-b1 receptor; the
collagen-modifying enzymes LOX, PLOD1, and PLOD2; and the extracellular matrix proteins COMP, FN1, TNC
and TNXB in synovial/capsule specimens from patients with idiopathic adhesive capsulitis. Possible associations
between the measured mRNA levels and clinical parameters were also investigated.
METHODS: We obtained glenohumeral joint synovium/capsule specimens from 9 patients with idiopathic
adhesive capsulitis who had not shown improvement in symptoms after 5 months of physiotherapy. Adhesive
capsulitis was confirmed in all patients by magnetic resonance imaging. We also obtained specimens from 8
control patients who had underwent surgery for acute acromioclavicular joint dislocation and who had
radiological indication of glenohumeral capsule alteration based on arthroscopic evaluation. mRNA expression
in the synovium/capsule specimens was analyzed by quantitative reverse transcription PCR. The B2M and HPRT1
genes were used as references to normalize target gene expression in the shoulder tissue samples.
RESULTS: The synovium/capsule samples from the patients with adhesive capsulitis had significantly higher TNC
and FN1 expression than those from the controls. Additionally, symptom duration directly correlated with
expression of TGFb1 receptor I.
CONCLUSION: Elevated levels of TNC and FN1 expression may be a marker of capsule injury. Upregulation of
TGFb1 receptor I seems to be dependent on symptom duration; therefore, TGFb signaling may be involved in
adhesive capsulitis. As such, TNC, FN1 and TGFb1 receptor I may also play roles in adhesive capsulitis by
contributing to capsule inflammation and fibrosis.
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’ INTRODUCTION
Adhesive capsulitis, or frozen shoulder, is a debilitating
condition in which patients present limited active and
passive glenohumeral motion. Adhesive capsulitis occurs in
3%-5% of the general population (1) and the main cause
of the painful restriction of movement is inflammatory
contracture of the joint capsule. The initial inflammation
seems to lead to capsular fibrosis, stiffness and pain (2).
Therefore, it has been hypothesized that similarities exist
between adhesive capsulitis and the fibrous contractures that
occur in Dupuytren disease (3,4). However, the molecular
mechanism responsible for the underlying glenohumeral
capsule inflammation and fibrosis is poorly understood.
Rodeo et al. suggested that cytokines, such as transform-
ing growth factor beta (TGFb), may be involved in the
inflammatory and fibrotic processes that occur in adhesive
capsulitis. These cytokines may cause abnormal regulation of
collagen expression and augment fibroblast proliferation (5).
Therefore, TGFb acts as a persistent stimulus that leads to
capsular fibrosis.
TGFb induces fibroblasts to synthesize, remodel and
contract extracellular matrix (ECM), making this cytokine aDOI: 10.6061/clinics/2016(06)07
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key mediator of the fibrotic response (6). TGFb is activated by
proteolytic cleavage (7) mediated by the signaling receptors
TGFb receptor I (TGFbR1) and TGFb receptor 2 (TGFbR2) (8).
TGFBR1 is the principal propagator of TGFb signaling (9).
TGFb1, a key member of the TGFb superfamily, regulates
the collagen-modifying enzymes lysyl oxidase (LOX) (10)
and lysyl hydroxylases 1 and 2 (encoded by the PLOD1 and
PLOD2 genes, respectively) (11-13). LOX plays a role in
connective tissue matrix biogenesis through the oxidation of
lysine residues in collagen and elastin, contributing to the
formation of covalent cross-links and thereby stabilizing
fibrous ECM proteins (14,15). In several fibrotic injuries,
TGFb1 controls the expression and enzymatic activity of
LOX (10).
Lysyl hydroxylases such as PLOD1 and PLOD2 promote
cross-linking in ECM molecules, which contribute to ECM
structural stability and maturation (16,17). Increased PLOD2
expression has been reported in fibroblasts isolated from
hypertrophic scars, keloids and palmar fascia from patients
with Dupuytren disease (18). To the best of our knowledge,
no previous studies have evaluated the roles of lysyl oxidase
and hydroxylase in adhesive capsulitis.
TGFb regulates and is regulated by several ECM proteins.
Cartilage oligomeric matrix protein (COMP), a glycoprotein
found in the ECM of joints, plays a catalytic role in
fibrillogenesis (19). Recent studies have shown that COMP
also directly binds members of the TGFb superfamily of
proteins, including TGFb1 (20). Haudenschild et al. showed
that TGFb1 displays enhanced bioactivity when bound to
COMP (20). In addition, TGFb1 appears to have the capacity
to induce COMP expression (21).
Fibronectin (FN), a glycoprotein encoded by the FN1 gene,
is involved in several biological processes, including cell
adhesion, tissue development and wound healing (22). FN
also has a role in TGFb regulation (23). Moreover, FN
expression increases under stimuli induced by TGFb (24).
Moreover, the tenascins (TN), including TNR, TNC and
TNX, are a highly conserved family of ECM glycoproteins.
TNR is expressed only in the brain, whereas TNC and TNX
are expressed in several organs and tissues, including in the
joints (25). TNC has an important role in modulating the
actions of TGFb (26) and is also regulated by TGFb (27).
TNXB seems to regulate collagen synthesis or deposition
(28). A recent study showed that TNX also regulates TGFb
bioavailability and modulates cell plasticity (29).
In the present study, we quantified the mRNA expression
of the TGFb1, TGFbR1, LOX, PLOD1, PLOD2, COMP, FN1,
TNC and TNXB genes in glenohumeral synovium/capsule
samples collected from patients with adhesive capsulitis and
from controls. We also evaluated how these mRNA levels are
associated with clinical features.
’ MATERIALS AND METHODS
Patients
The current study used a case-control study design (level 3
evidence). All patients and controls were treated at the
Hospital São Paulo of the Universidade Federal de São
Paulo. Each patient agreed to participate by signing a written
consent form before data and sample collection. This study
was approved by the ethics committee of the Universidade
Federal de São Paulo (approval number: CEP 1918/11).
The case group was composed of 9 patients with
idiopathic adhesive capsulitis of the shoulder in freezing or
frozen stages who were diagnosed by clinical evaluation.
During the clinical evaluations, the patients presented with
pain, loss of motion and severe limitations during daily
activities; no history of trauma or previous shoulder
pathologies; and functional restriction of both active and
passive shoulder motion. Magnetic resonance imaging (MRI)
was used to exclude secondary stiff shoulder. The patients
underwent arthroscopic shoulder capsular release after a
concerted effort was made to treat them with conservative
management for at least 5 complete months. In all cases, the
physiotherapy had failed. Additionally,patients meeting the
following exclusion criteria were omitted: generalized
arthritis; previous compromise of the shoulder, such as
major trauma, fracture, rotator cuff tear, calcifying tendinitis,
or shoulder instability; and superior labral anterior and
posterior (SLAP) lesions. Additionally, patients who did not
agree with the informed consent terms were excluded. All
enrolled patients underwent an arthroscopic procedure.
The control group consisted of 8 physically active subjects
who underwent arthroscopically assisted treatment for acute
acromioclavicular dislocation. None of the controls presented
with a history of adhesive capsulitis. Moreover, radiological
indication of glenohumeral capsule alteration was detected.
A standard complete joint evaluation by arthroscopy
confirmed that the controls did not present any other
concomitant pathology in the shoulder.
All patients answered a preoperative questionnaire con-
cerning gender, age at surgery, age of pain onset, duration of
symptoms, bilaterality, suprascapular nerve block, physical
activity, type of work and smoking habits (Table 1).
Tissue samples
Tissue samples of approximately 2 mm3 were obtained
from the anterior-inferior portion of the glenohumeral
capsule during the arthroscopic procedure. To reduce
sampling variation, only two of the authors (CC and BE)
were responsible for collecting the tissue samples. The
samples were collected as previously described (30-32). As
the synovium is adhered to the capsule, it cannot be
separated from the capsule using arthroscopic instruments.
Table 1 - Distribution of clinical variables for patients with
adhesive capsulitis.
Variable Distribution
Age at surgery, years [median (IQR)] 51.7 (16.5)
Age at symptom onset, years [median (IQR)] 50.4 (14.5)
Gender [N(%)]
Male 3 (33)
Female 6 (67)
Duration of condition, months [median (IQR)] 10.67 (10)
Bilaterality [N(%)]
No 6 (67)
Yes 3 (33)
Practice of sports involving the upper limbs [N (%)]
No 8 (89)
Yes 1 (11)
Type of job [N(%)]
Non-manual 6 (67)
Manual 3 (33)
Smoking habits [N(%)]
Non-smoker 8 (89)
Smoker 1 (11)
N: number of patients; IQR: interquartile range.
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To provide immediate stabilization of RNA, all synovium/
capsule specimens were instantly preserved in Allprotect Tissue
Reagents (Qiagen, Germany) and then stored at -20 oC.
RNA extraction
An AllPrep DNA/RNA/miRNA Universal Kit (Qiagen,
Germany) was used to purify total RNA from the
synovium/capsule specimens. Tissue Lyser LT equipment
(Qiagen, USA) was used to mechanically lyse the tissue
samples. A NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, USA) was used to determine RNA concentration
and quality. RNA integrity was verified by 1% agarose gel
electrophoresis. The RNA samples were stored at -80 oC.
mRNA expression analysis
Reverse transcription-quantitative polymerase chain reac-
tion (RT-qPCR) was used to evaluate mRNA expression.
First, a High-Capacity cDNA Archive kit (Life Technologies,
USA) was used for cDNA synthesis. Then, RT-qPCR was
performed as previously described using a ViiA 7 Real-Time
PCR System (Life Technologies, USA) (30). To exclude
technical variations, target and reference genes (Table 2)
were analyzed on the same TaqMan Low-Density Array
(TLDA) cards (Life Technologies, USA). All qPCR assays
were performed in triplicate. The B2M and HPRT1 genes
were used as reference genes to normalize sample input
amount. These genes were chosen based on a previous study
of suitable internal controls for the evaluation of mRNA
expression in shoulder capsule samples (33).
The relative cycle threshold method (Crt method) was
used to quantify mRNA expression. In this method, the
lower the cycle threshold value (Crt) value, the greater the
number of initial target copies in the sample. Thus, low Crt
values indicate high gene expression. The expression of
the target genes was determined using the following
equation: DCrt=target gene Crt – the mean of the reference
genes Crt.
Statistical analysis
All DCrt values are shown as the median with the
interquartile range (IQR).
The gender and age distributions between the patients
with adhesive capsulitis and the controls were compared
using the Chi-square test and the Mann-Whitney test,
respectively. The Mann-Whitney test was also applied to
compare mRNA levels between the cases and the controls, as
well as to investigate the possible associations between
mRNA expression and preoperative clinical variables, such
as gender, practice of sports involving the upper limbs, type
of job (manual versus non-manual job) and smoking habits.
Spearman’s correlation was used to assess possible correla-
tions between mRNA levels and duration of symptoms or
age at surgery: a value below 0.40 was considered a weak
correlation, a value between 0.40 and 0.59 was considered a
moderate correlation, a value between 0.6 and 0.79 was
considered a strong correlation and a value X0.80 was
considered a very strong correlation. For all analyses, a
p-valueo0.05 was considered statistically significant. Statis-
tical analyses were performed using PASW (SPSS) software,
version 18 (SPSS Inc., Chicago, USA).
Table 2 - Summary of reference gene and target gene assays.
Gene symbol Name Assay*
TGFb1 Transforming growth factor, beta 1 Hs00998133_m1
TGFbR1 Transforming growth factor, beta receptor 1 Hs00610320_m1
LOX Lysyl oxidase Hs00942480_m1
PLOD1 Lysyl hydroxylases 1 Hs00609368_m1
PLOD2 Lysyl hydroxylases 2 Hs01118190_m1
COMP Cartilage oligomeric matrix protein Hs00164359_m1
FN1 Fibronectin 1 Hs00365052_m1
TNC Tenascin C Hs01115665_m1
TNXB Tenascin XB Hs00372889_g1
B2M** Beta-2-microglobulin Hs00984230_m1
HPRT1** Hypoxanthine phosphoribosyl-transferase Hs02800695_m1
* TaqMan probes were purchased as assay-on-demand products for gene expression (Life Technologies, USA).
** Reference genes for target gene expression normalization.
Table 3 - Gene expression patterns in the glenohumeral capsules of patients with adhesive capsulitis and in controls.
Gene Cases [DCrt; Median (IQR)] Controls [DCrt; Median (IQR)] p-value
TGFb1 0.99 (0.62) 0.57 (0.52) 0.149
TGFbR1 1.77 (1.04) 1.47 (0.73) 0.923
LOX 3.16 (2.27) 3.37 (1.52) 0.700
PLOD1 0.95 (0.62) 1.07 (0.48) 0.336
PLOD2 2.39 (0.82) 3.11 (1.08) 0.068
COMP 1.39 (3.53) -0.01 (2.05) 0.336
FN1 -5.65 (1.53) -4.85 (0.79) 0.043*
TNC -1.48 (1.72) 0.36 (1.31) 0.005*
TNXB -2.55 (1.02) -2.79 (1.03) 0.290
* Significant difference between groups by Mann-Whitney test (po0.05). IQR: interquartile range. A lower delta cycle threshold value (DCrt) indicates
higher gene expression.
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’ RESULTS
Differences between cases and controls
Table 1 presents the clinical variables of the study
participants. In the control group, 1 (12.5%) individual was
female and 7 (87.5%) were males. The median age at the time
of surgery was 31.44 years (IQR=13.5). The gender distribu-
tion did not differ between the study groups (p=0.05).
However, the controls were significantly younger than the
patients with adhesive capsulitis (p=0.012, Mann-Whitney
test).
Table 3 shows the median and IQR values for the
expression levels of the studied genes in the samples from
the patients and the controls. The patients with adhesive
capsulitis had higher levels of TNC (p=0.005; Figure 1A) and
FN1 (p=0.043; Figure 1B) expression compared to the
controls. No other significant differences were observed
between the patients and the controls (p40.05).
Associations between the clinical characteristics of
adhesive capsulitis and mRNA expression
Figure 2 shows the correlations between the duration of
adhesive capsulitis symptoms and the expression levels
of the studied genes. In the tissue samples, the expression of
TGFbR1 mRNA was significantly and directly correlated
with the duration of symptoms (r=-0.731, p=0.025;
Figure 2B).
No correlation was found between the age of the patients
at the time of surgery and the age at symptom onset
(p40.05). Additionally, no association was found between
the mRNA levels of the studied genes and any of the clinical
features assessed in the patients with adhesive capsulitis
(p40.05).
’ DISCUSSION
Although adhesive capsulitis is considered a self-limited
disease, some patients show little to no improvement,
maintain a limited range of motion and continue to
experience shoulder pain. Non-operative treatment is the
initial approach used for adhesive capsulitis. However,
operative treatment (such as arthroscopic capsular release)
may be considered when patients remain in pain and do not
regain satisfactory range of motion after prolonged non-
operative treatment (34,35).
In this study, we found higher levels of TNC and FN1
expression in glenohumeral synovium/capsule samples
collected from patients with adhesive capsulitis compared
to those collected from controls. TNC immunoreactivity was
previously reported in other shoulder diseases, including in
rotator cuff tendon tears and in the subacromial bursa of
patients with impingement syndrome (36,37). In addition,
we have previously found that both TNC and FN1 mRNA
levels were upregulated in the glenohumeral capsules of
patients with traumatic anterior shoulder instability (unpub-
lished data). TNC is a large hexameric ECM glycoprotein
that has roles in cell adhesion, fibroblast migration and other
processes related to tissue remodeling and wound healing
(38,39). TNC is specifically expressed following tissue
damage, being upregulated within 24 h of injury (38). It is
activated after local injury and down-regulated after tissue
repair or scarring is completed (40). Persistent expression of
TNC is associated with several fibrotic diseases and with
chronic non-healing wounds (38).
Therefore, we hypothesize that increased TNC expression
may be a marker of capsule injury and the genes involved
may participate in inflammatory and fibrotic processes in the
glenohumeral capsule.
FN is essential for collagen fibril assembly (41). During the
early phase of wound healing, FN is deposited at sites of
injury and can induce inflammation; increase ECM deposi-
tion, including of FN and collagen; and activate fibroblasts.
These pathways can create a vicious cycle that eventually
induces keloid formation or fibrosis (42). Additionally, FN
has been previously associated with Dupuytren’s contracture
(24). In this disease, FN can be found in its oncofetal form
(43,44). Additionally, upregulation of FN1 has been asso-
ciated with fibrosis in inflammatory orbital diseases (45),
hepatic fibrosis (46), idiopathic pulmonary fibrosis (47,48)
and liver fibrosis (49). These relationships indicate that this
molecule may also be involved in the pathogenesis of other
fibrosing diseases. Interestingly, Altrock et al. showed that
blocking FN deposition using an FN assembly inhibitor
(pUR4) resulted in decreased collagen accumulation and
improved liver function during liver fibrogenesis (50).
Although only a slight increase in FN1 expression was
detected in the glenohumeral capsules of the patients with
adhesive capsulitis in the current study, our results suggest
that FN1 may play a role in the fibrotic process. Further
investigation is still necessary to understand the dynamic
transcriptional regulation of FN1 that occurs within the
shoulder capsule.
We also observed that the expression of TGFbR1 mRNA in
the capsule was directly correlated with symptom duration
in the patients with adhesive capsulitis. To the best of our
knowledge, only one previous study has evaluated the role
of the TGFb receptor in adhesive capsulitis (5). Rodeo et al.
analyzed both TGFb and its receptor in capsule and
synovium samples collected from patients with adhesive
capsulitis and in those collected from controls (5). They
Figure 1 - TNC (A) and FN1 (B) expression levels in capsule samples collected from patients with adhesive capsulitis and controls. A lower
delta cycle threshold value (DCrt) indicates higher gene expression. Box plots show the median and interquartile range. *A significant
difference between groups by Mann-Whitney test (po0.05).
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performed a semi-quantitative analysis by comparing the
frequency of positive staining between the groups. The
authors described that the synovial and capsular cells of
patients with adhesive capsulitis and synovitis showed clear
TGFb and TGFbR staining, whereas no or minimal staining
was observed in the normal tissue specimens. The blood
vessels of the affected tissues also presented staining for both
proteins. Moreover, there was a higher frequency of positive
TGFb and TGFbR staining in the synovial cells of the patients
with adhesive capsulitis. In addition, there was a greater
frequency of positive TGFb staining in the ECMs of patients
with adhesive capsulitis compared to the controls, particu-
larly in the capsule tissue.
In the present study, we found no differences in the
expression of TGFb1 and TGFbR1 mRNA between the cases
and the controls. Because the synovium is adhered to the
capsule and cannot be separated from the capsule using
arthroscopic instruments, our investigation did not discrimi-
nate between gene expression in synovial and capsular
tissues. However, molecular alterations in both tissues are
important in adhesive capsulitis (51). In addition, our study
is the first to use a quantitative approach to evaluate the role
of TGFbR1 in adhesive capsulitis. Our results suggest that
TGFbR1 may have a role in adhesive capsulitis, especially in
the long-term disease.
To the best of our knowledge, this study is the first to
quantify TGFb1, TGFbR1, LOX, PLOD1, PLOD2, COMP,
FN1, TNC and TNXB mRNA expression in the shoulder
capsules of patients with adhesive capsulitis. However, this
study has some limitations. First, few patients with adhesive
capsulitis are surgically treated; as such, there is a limited
number of tissue samples available for studies of gene
expression (5,35,52-59). Therefore, some of our statistical
analyses had reduced power to detect significant differences
between the studied groups and false-negative results may
have occurred. Second, we included patients who failed in
conservative treatment in different phases of frozen shoulder,
some in freezing and others in frozen stages. This hetero-
geneity may have also contributed to false negatives. Third,
molecular alterations may occur in other capsule regions and
may have a different etiological role in capsular injury (30-
32). We evaluated the AI region because this portion of the
capsule presented macroscopic injuries (i.e., a high level of
inflammation) during arthroscopic examination of the
studied patients. Although we did not detect a correlation
between age and gene expression in the tissue samples
Figure 2 - Correlation between gene expression and duration of adhesive capsulitis (months). A) TGFb1; B) TGFbR1; C) LOX; D) PLOD1;
E) PLOD2; F) COMP; G) FN1; H) TNC; and I) TNXB. r: Spearman correlation coefficient ("rho"). *Significant correlation (po0.05). A lower
delta cycle threshold value (DCrt) indicates higher gene expression.
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collected from the patients with adhesive capsulitis, it is
important to highlight that the age distribution between the
patients and the controls was different. Thus, we cannot
exclude that age might have influenced our findings. Finally,
additional analysis of the protein products of the studied
genes may be interesting because protein function is also
affected by post-transcriptional and post-translational
regulation.
Elevated expression of TNC and FN1 mRNA may be a
marker of capsule injury and may be involved in capsule
inflammation and fibrosis. Upregulation of TGFbR1 seems
to be related to symptom duration in adhesive capsulitis;
therefore, TGFb signaling may play a role in this
condition.
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